Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib

NCT01323400 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT01323400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01323400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
February 29, 2016
Enrollment
81 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

gist